Roche Pharmaceutical Development and Sales Overview
SMA franchise: Evrysdi with strong global momentum
Well-positioned to become #1 worldwide
CHFM
350
300
250
200
>500%
150
100
50
Q3 20
Q3 21
■US
■Europe
International
Japan
CER-Constant Exchange Rates; SMA-spinal muscular atrophy
YoY CER growth
+93%
Q3 22
Q3 update
•
>7,000 patients treated worldwide (commercial, clinical
trials, compassionate use)
Retention rate in first 12 months of ~90% globally
US: Growth driven by switch and naive patient starts
including patients <2 months old
• Ex-US: Continued strong growth and share gains in all major
markets
Positive Ph II (JEWELFISH) 2 year data presented at WMS;
largest SMA study in previously treated patients
Outlook 2022
•
Continued growth and market share gains across all market
segments expected
• EU: Label extension (<2 months old) based on Ph II
RAINBOWFISH expected
Roche
27View entire presentation